*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company’s drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
Market Cap:14.1M; Shares Outstanding:8.5M; Short Interest: 3.64%; Q3 2019(9/30/19): Cash 10.02M. Loss 7.84M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 19，no change
Shares hold: 55.83k shares. no change
shares% hold: 1.39%，no change